39 kinds of low price drugs in Fujian

Source: pharmaceutical economic news, September 26, 2014, the notice of Fujian Provincial Price Bureau on the establishment of drug price monitoring and reporting system (hereinafter referred to as "the notice") was issued recently, requiring the establishment of low-cost drug price monitoring and reporting system, understanding the actual sales price changes of low-cost drugs in the market, and providing the monitoring catalogue involving 39 products Fujian became the first province to establish a low-cost drug monitoring system It is understood that most of the varieties to be monitored this time are national low-cost drugs, while a large number of exclusive varieties supplemented by Fujian Province are not included in the scope of monitoring This may provide some reference for other provinces (cities) to develop the monitoring varieties catalogue According to the reporter's observation, the market opportunity of the low-cost drug catalogue policy has not yet been realized, and the national and local positioning of low-cost drugs has not impacted the status of base drugs, nor given more reform expectations to the low-cost drug catalogue Local strict control of exclusive varieties? According to the notice, the price monitoring system is mainly aimed at low-cost drug varieties It monitors the sales prices of 39 key monitored varieties in the catalogue in public hospitals and retail pharmacies, and stipulates that the sales prices shall be reported once a month It is mainly based on the notice on improving the price management of low-cost drugs issued by the national development and Reform Commission in May this year The competent price department should monitor the production cost and actual purchase and sale price of low-cost drugs, and focus on the monitoring of exclusive production or monopoly drugs According to the statistics of some organizations, the monitored varieties include weide'an tablet of Jinling Pharmaceutical Co., Ltd., Zhike orange granules of Kangzhi Pharmaceutical Co., Ltd., yangxueyin oral liquid of Aodong, Dendrobium night light pill of Tongrentang, ethinylestradiol and cyproterone of Xianju Pharmaceutical Co., Ltd., compound progesterone of Northeast Pharmaceutical Co., Ltd Most of the monitored varieties are listed in the national low-cost drug catalog, and some are not At the same time, it is worth noting that according to the statistics of low-cost drug supplement catalogue of each province, more than ten exclusive varieties included in the catalogue by more than 20 provinces (cities) are also included in the low-cost supplement catalogue of Fujian Province, but not included in the monitoring scope For example, among the chemical drugs, the compound pseudoephedrine hydrochloride of mesk and naproxen sustained-release capsule of Enhua Pharmaceutical Co., Ltd; In terms of Chinese patent medicine, Hunan lepang's Maren capsule, Shenyang Hongyao's Shenyang Hongyao capsule (tablet), Baiyunshan Zhongyi's Wushe antipruritic pill, Guizhou Huangguoshu's yanlishanghan dropping pill, Henan Fushen's Yuanhu Zhitong oral liquid, Kunming traditional Chinese medicine factory's Zhike pill, Jiangxi Jiuhua's Hemorrhoids Suppository and other products are not included in the monitoring scope The above exclusive varieties cover more than 20 provinces in the low-cost drug supplement catalogue of 30 provinces Does this mean that these exclusive varieties will be "protected" by the policy? Or does it not belong to the category of key monitoring? No matter what, the monitoring catalogue issued by Fujian this time, or provide some reference for the development of other provinces (cities) monitoring catalogue, the development of enterprise related variety market strategy, etc In fact, there is no strong support for the positive effect of the catalogue Since the establishment of the catalogue of low-cost drugs at the national level, there has been a heated discussion on the market opportunities of the catalogue, including the debate on the use of low-cost drugs and base drugs Guotai Junan believes that the direct online purchase of low-cost drugs is the embodiment of the marketization of drug price management, the correction of the simple administrative price reduction, and the reversal of the past practice that the drug price can only be reduced but not increased The new control mode also indicates that the drug price management idea and direction of the national development and Reform Commission have been adjusted: no longer obsessed with some products with lower daily average cost, more attention will be paid to products with higher daily average cost But with regard to market opportunities, Guotai Junan believes that the main beneficiaries may be some exclusive varieties In the hospital channel, without price bidding, the price system will be better maintained, but whether the price can be raised depends on the local rules and the coordination between enterprises and local governments However, considering that the supporting policies of the local health and family planning commission are more influential, most enterprises are currently waiting for the follow-up policies According to the analysis of a pharmaceutical manufacturer in Shanghai, the relevant person in charge of the Department of drug administration of the state health and Family Planning Commission has repeatedly stated that the list of commonly used low-cost drugs is to ensure the production and supply of commonly used low-cost drugs in clinical practice, without mentioning "promoting use", etc., which may be regarded as the most fundamental difference between the list of low-cost drugs and the implementation of the list of base drugs Or it is also the original intention that low-cost drugs need to develop monitoring mechanism It is reported that since the introduction of the low-cost drug policy, some manufacturers such as Jiaying Pharmaceutical Co., Ltd., China New Pharmaceutical Co., Ltd and handmade Pharmaceutical Co., Ltd have tried to raise their prices, but more manufacturers, including the exclusive variety manufacturers, have not taken obvious actions, which to some extent reflects that the direction of the implementation of the policy is very clear At the local level, the newly issued Zhejiang bidding plan is also clear The reference price of low-cost drugs is based on the lowest transaction price in the province, and the purchase price is 30% higher than the reference price, so the transaction should be suspended All kinds of signs show that "the opportunity of low-cost drugs" has not been realized for many varieties, and there is no strong support for how much space there is in the future.